Search the Newsreel

Ascendis Pharma A/S Revenue Breakdown – NASDAQ:ASND

Ascendis Pharma A/S (NASDAQ: ASND) generated a total revenue of $845.80 million last year, with its Pharmaceutical segment being the largest contributor at $812.73 million. A significant portion of this revenue, $616.64 million, came from the United States market. This indicates a substantial increase …

Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know

Ascentage Pharma Group International - Unsponsored ADR (AAPG) closed the last trading session at $18.29, gaining 9.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any …

ASND|Ascendis Pharma A/S|Price:256.235|Chg%:+2.375

This article provides a detailed company profile for Ascendis Pharma A/S (ASND), a Denmark-based pharmaceutical company. It outlines their business scope, manufacturing products for growth hormone deficiency, endocrinology, CNS disorders, infectious diseases, and diabetes, and lists key financial data and market performance metrics. The …

Ascentage Pharma Group International (AAPG) Cash Flow

This article provides an overview of Ascentage Pharma Group International's (AAPG) cash flow, detailing its operating, investing, and financing activities. It explains what each type of cash flow represents and how much the company generated or used in recent fiscal periods. Key financial figures …

Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.2% - What's Next?

AAPG|Ascentage Pharma Group International|Price:18.290|Chg%:-0.615

This article provides a financial summary of Ascentage Pharma Group International (AAPG), highlighting its stock price, market capitalization, and upcoming earnings report. It emphasizes the availability of financial analysis tools on TradingKey, allowing investors to review income statements, balance sheets, and cash flow statements. …

Ascentage CEO ranks No. 3 in small molecules on list of 60 leaders

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category among 60 global pharmaceutical leaders. The recognition highlights his leadership in developing a small-molecule oncology pipeline, including …

TerrAscend Corp. Revenue Breakdown – TSX:TSND

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Short Interest Down 87.2% in July

Ascentage Pharma Group International (NASDAQ:AAPG) experienced a significant 87.2% decline in short interest during July, falling to 20,246 shares as of July 15th. Despite this reduction, analysts maintain a bullish outlook with a consensus "Buy" rating and an average price target of $46.43, even …

Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns

Artisan Small Cap Fund reduced its position in Ascendis Pharma A/S (ASND) during Q2 2026 due to lawsuit concerns, despite maintaining conviction in the company's long-term prospects. The fund noted mixed recent results for ASND, with revenues below expectations but EPS exceeding estimates, and …

Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ascendis Pharma A/S (ASND), highlighting its current earnings forecast score of 9.00, which ranks 15th in the Biotechnology & Medical Research industry. Analysts have a strong buy rating for the stock with an average price target of …

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's Why

Ascentage Pharma Group International (NASDAQ:AAPG) shares gapped down prior to trading on Friday, opening at $18.52 after closing at $19.33, and later trading around $18.07. Despite this dip, Wall Street analysts maintain a bullish outlook with a consensus "Buy" rating and a price target …

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $275

Morgan Stanley has reiterated its Buy rating on Ascendis Pharma A/S (ASND.US) and increased its price target to $275. This continued positive outlook suggests the firm sees strong potential for the company's valuation growth.

Ascentage Pharma Group Internat (AAPG) Stock Analysis: Uncovering a Potential 158% Upside

Ascentage Pharma Group International (AAPG) is a clinical-stage biotechnology company focused on cancer, chronic hepatitis B, and age-related diseases, showing potential for significant growth. Analysts project a potential upside of 158.88% despite the company currently being in a developmental phase with negative earnings and …

Ascentage Pharma Sets Up $200 Million Nasdaq ATM Offering Program

Ascentage Pharma Group International has established a $200 million At-The-Market (ATM) offering program on Nasdaq. The biopharmaceutical company filed a shelf registration statement with the SEC to enable flexible capital raising in the U.S. market through the sale of American depositary shares. This move …

Ascentage Pharma (NASDAQ: AAPG) targets US$200M ATM ADS sale

Ascentage Pharma Group International plans an at-the-market (ATM) equity program to sell up to US$200 million in American depositary shares (ADSs) on Nasdaq through Citigroup, Deutsche Bank, and BTIG. The proceeds are intended to fund research and development, clinical trials, commercialization, and general corporate …

Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Ascendis Pharma A/S (ASND), showing its current trading price and daily percentage change. It also includes sections for analyst ratings, although none are currently available, and mentions the lack of earnings information for the company. …

ASND5566766 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Ascendis Pharma A/S bond with the identifier ASND5566766. It details that the bond has a current coupon rate of 2.25% and its next interest payment is scheduled for October 1, 2026. The profile offers an overview …

Ascent Resources plc (LSE: AST) Share Price, AST Stock News, AST Share Price & Updates

(ASND) Price Dynamics and Execution-Aware Positioning

This article analyzes Ascendis Pharma A/s (NASDAQ: ASND) price dynamics, highlighting a weak near

ASND5566766 Bond Profile — Key Metrics

This article provides key metrics for the ASND5566766 bond issued by Ascendis Pharma A/S. It details the bond's coupon rate, maturity date, issuer information, and other crucial financial data. The bond is a 2.25% bond maturing on April 1, 2028.

Price to earnings forward of Ascendis Pharma A/S – DUS:A710

This article provides the "Price to earnings forward" metric for Ascendis Pharma A/S (DUS:A710) on the Dusseldorf Stock Exchange. It is a financial data point presented by TradingView, with data sourced from ICE Data Services and FactSet. The page is concise and focuses solely …

Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57

Ascendis Pharma A/S granted 14,060 warrants to employees on July 14, 2026, with an exercise price of US $265.57 per share. These warrants have a vesting schedule where 25% vest after one year, and the remaining 75% vest monthly over 36 months, subject to …

Ascendis Pharma AS (ASND) extends four-week biotech rally to 30.4%

The weekly setup remains active, but lighter turnover tempers the strength behind the advance.

Ascent Resources loses arbitration case against Slovenia By Investing.com

Ascendis Pharma’s 30% month reaches the high, but July participation cools to 0.8x

Ascendis Pharma closed at $274.50, only 0.1% below its 52-week high, after a four-week advance of 30.4%. The Trend backdrop remains active, but lighter volume and a wide Fair Value premium keep the weekly read balanced rather than emphatic.

Ascendis Pharma (ASND) Joins Multiple Russell Indexes

TSND Forecast — Price Target — Prediction for 2027

SMALL-CAP MOVERS: Hope, arbitration and a €656 million question. Ascent Resources braces for its day of reckoning

Ascent Resources Awaits Final Decision in Slovenia Arbitration Dispute (AST)

Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation

CICT vs CapitaLand Ascendas REIT: Which CapitaLand Giant is the Better Buy?

Singapore Shares Clock Losses as US Iran Fire Exchange Threatens Peace Talks; Ascent Bridge Zooms 50%

Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position

Ascendis Pharma (ASND) Profit Swing To €10.2 EPS Tests Earnings Quality Concerns

Ascendis Pharma Reports First Quarter 2026 Financial Results